Co-Authors
This is a "connection" page, showing publications co-authored by Ilad Alavi Darazam and Firouze Hatami.
Connection Strength
0.705
-
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. Int Immunopharmacol. 2021 Oct; 99:107969.
Score: 0.239
-
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. Int Immunopharmacol. 2021 Oct; 99:107916.
Score: 0.238
-
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. Trials. 2020 Oct 26; 21(1):880.
Score: 0.227